A single centre experience with sequential and concomitant chemoradiotherapy in locally advanced stage IV tonsillar cancer

Radiation Oncology

Volumn 5, Issue 1, 2010, Pages

  D Prestwich, Robin J ^a   Kancherla, Kiran ^a   Oksuz, Didem C ^a   Williamson, Deborah ^a   Dyker, Karen E ^a   Coyle, Catherine ^a   Sen, Mehmet ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; FLUOROURACIL; ANTINEOPLASTIC AGENT;

ADJUVANT THERAPY; ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE NECROSIS; CANCER CENTER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CAUSE SPECIFIC SURVIVAL; CHEMORADIOTHERAPY; CLINICAL ARTICLE; DISTANT METASTASIS; DRUG FATALITY; DRUG SUBSTITUTION; DYSPHAGIA; FEMALE; FOLLOW UP; GASTROSTOMY; HUMAN; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NASOGASTRIC TUBE; NECROSIS; NEUTROPENIA; NUTRITIONAL SUPPORT; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SKIN MANIFESTATION; SQUAMOUS CELL CARCINOMA; TONSIL CANCER; TREATMENT OUTCOME; TRISMUS; VOMITING; ADJUVANT CHEMOTHERAPY; CANCER STAGING; DISEASE COURSE; DRUG ADMINISTRATION; EVALUATION; METHODOLOGY; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; SURVIVAL; TONSIL TUMOR;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TONSILLAR NEOPLASMS;

EID: 78650273611     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-5-121     Document Type: Article

References (41)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55(2):74-108. 10.3322/canjclin.55.2.74, 15761078.
2. Corry J, Peters LJ, Rischin D. Optimising the therapeutic ratio in head and neck cancer. Lancet Oncol 2010, 11(3):287-91. 10.1016/S1470-2045(09)70384-5, 20202613.
3. Prestwich R, Dyker K, Sen M. Improving the therapeutic ratio in head and neck cancer. Lancet Oncol 2010, 11(6):512-3. 10.1016/S1470-2045(10)70060-7, 20522378.
4. Lefebvre JL, Chevalier D, Luboinski B, Kirkpatrick A, Collette L, Sahmoud T. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst 1996, 88(13):890-9. 10.1093/jnci/88.13.890, 8656441.
5. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. The Department of Veterans Affairs Laryngeal Cancer Study Group. N Engl J Med 1991, 324(24):1685-90. 10.1056/NEJM199106133242402, 2034244.
6. Pignon JP, Bourhis J, Domenge C, Designe L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 2000, 355(9208):949-55.
7. Pignon JP, le Maitre A, Maillard E, Bourhis J. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 2009, 92(1):4-14. 10.1016/j.radonc.2009.04.014, 19446902.
8. Browman GP, Hodson DI, Mackenzie RJ, Bestic N, Zuraw L. Choosing a concomitant chemotherapy and radiotherapy regimen for squamous cell head and neck cancer: A systematic review of the published literature with subgroup analysis. Head Neck 2001, 23(7):579-89. 10.1002/hed.1081, 11400247.
9. Vokes EE, Kies MS, Haraf DJ, Stenson K, List M, Humerickhouse R, et al. Concomitant chemoradiotherapy as primary therapy for locoregionally advanced head and neck cancer. J Clin Oncol 2000, 18(8):1652-61.
10. Denis F, Garaud P, Bardet E, Alfonsi M, Sire C, Germain T, et al. Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol 2004, 22(1):69-76. 10.1200/JCO.2004.08.021, 14657228.
11. Prestwich RJ, Shakespeare D, Waters S. The rationale for and current role of chemoradiotherapy. J Radiotherapy in Practice 2007, 6:11-9.
12. Posner MR, Hershock DM, Blajman CR, Mickiewicz E, Winquist E, Gorbounova V, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007, 357(17):1705-15. 10.1056/NEJMoa070956, 17960013.
13. Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 2007, 357(17):1695-704. 10.1056/NEJMoa071028, 17960012.
14. Cancer Research UK Cancer Statistics. Accessed 11th June 2010., http://info.cancerresearchuk.org/cancerstats/types/oral/incidence/
15. Mehanna H, Jones TM, Gregoire V, Ang KK. Oropharyngeal carcinoma related to human papillomavirus. BMJ 2010, 340:c1439. 10.1136/bmj.c1439, 20339160.
16. Mendenhall WM, Amdur RJ, Stringer SP, Villaret DB, Cassisi NJ. Radiation therapy for squamous cell carcinoma of the tonsillar region: a preferred alternative to surgery?. J Clin Oncol 2000, 18(11):2219-25.
17. Dodwell D, Crellin A. Waiting for radiotherapy. BMJ 2006, 332(7533):107-9. 10.1136/bmj.332.7533.107, 1326942, 16410589.
18. Ash D, Barrett A, Hinks A, Squire C. Re-audit of radiotherapy waiting times 2003. Clin Oncol (R Coll Radiol) 2004, 16(6):387-94.
19. Huang J, Barbera L, Brouwers M, Browman G, Mackillop WJ. Does delay in starting treatment affect the outcomes of radiotherapy? A systematic review. J Clin Oncol 2003, 21(3):555-63. 10.1200/JCO.2003.04.171, 12560449.
20. Henk JM. Controlled trials of synchronous chemotherapy with radiotherapy in head and neck cancer: overview of radiation morbidity. Clin Oncol (R Coll Radiol) 1997, 9(5):308-12.
21. Paccagnella A, Orlando A, Marchiori C, Zorat PL, Cavaniglia G, Sileni VC, et al. Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: a study by the Gruppo di Studio sui Tumori della Testa e del Collo. J Natl Cancer Inst 1994, 86(4):265-72. 10.1093/jnci/86.4.265, 8158680.
22. Zorat PL, Paccagnella A, Cavaniglia G, Loreggian L, Gava A, Mione CA, et al. Randomized phase III trial of neoadjuvant chemotherapy in head and neck cancer: 10-year follow-up. J Natl Cancer Inst 2004, 96(22):1714-7. 10.1093/jnci/djh306, 15547184.
23. Domenge C, Hill C, Lefebvre JL, De Raucourt D, Rhein B, Wibault P, et al. Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma. French Groupe d'Etude des Tumeurs de la Tete et du Cou (GETTEC). Br J Cancer 2000, 83(12):1594-8. 10.1054/bjoc.2000.1512, 2363468, 11189100.
24. Radiotherapy Dose-Fractionation. 2006, Royal College of Radiologists.
25. Fowler JF. Optimum overall times II: Extended modelling for head and neck radiotherapy. Clin Oncol (R Coll Radiol) 2008, 20(2):113-26.
26. Huguenin P, Beer KT, Allal A, Rufibach K, Friedli C, Davis JB, et al. Concomitant cisplatin significantly improves locoregional control in advanced head and neck cancers treated with hyperfractionated radiotherapy. J Clin Oncol 2004, 22(23):4665-73. 10.1200/JCO.2004.12.193, 15534360.
27. Calais G, Alfonsi M, Bardet E, Sire C, Germain T, Bergerot P, et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst 1999, 91(24):2081-6. 10.1093/jnci/91.24.2081, 10601378.
28. Brizel DM, Esclamado R. Concurrent chemoradiotherapy for locally advanced, nonmetastatic, squamous carcinoma of the head and neck: consensus, controversy, and conundrum. J Clin Oncol 2006, 24(17):2612-7. 10.1200/JCO.2005.05.2829, 16763273.
29. Paccagnella A, Ghi MG, Loreggian L, Buffoli A, Koussis H, Mione CA, et al. Concomitant chemoradiotherapy versus induction docetaxel, cisplatin and 5 fluorouracil (TPF) followed by concomitant chemoradiotherapy in locally advanced head and neck cancer: a phase II randomized study. Ann Oncol 2010, 21(7):1515-22. 10.1093/annonc/mdp573, 20032123.
30. Machtay M, Moughan J, Trotti A, Garden AS, Weber RS, Cooper JS, et al. Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. J Clin Oncol 2008, 26(21):3582-9. 10.1200/JCO.2007.14.8841, 18559875.
31. Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010, 11(1):21-8. 10.1016/S1470-2045(09)70311-0, 19897418.
32. Bhide SA, Ahmed M, Barbachano Y, Newbold K, Harrington KJ, Nutting CM. Sequential induction chemotherapy followed by radical chemo-radiation in the treatment of locoregionally advanced head-and-neck cancer. Br J Cancer 2008, 99(1):57-62. 10.1038/sj.bjc.6604444, 2453042, 18560402.
33. Hitt R, Lopez-Pousa A, Martinez-Trufero J, Escrig V, Carles J, Rizo A, et al. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol 2005, 23(34):8636-45. 10.1200/JCO.2004.00.1990, 16275937.
34. Vokes EE, Stenson K, Rosen FR, Kies MS, Rademaker AW, Witt ME, et al. Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanced head and neck cancer. J Clin Oncol 2003, 21(2):320-6. 10.1200/JCO.2003.06.006, 12525525.
35. Machtay M, Rosenthal DI, Hershock D, Jones H, Williamson S, Greenberg MJ, et al. Organ preservation therapy using induction plus concurrent chemoradiation for advanced resectable oropharyngeal carcinoma: a University of Pennsylvania Phase II Trial. J Clin Oncol 2002, 20(19):3964-71. 10.1200/JCO.2002.11.026, 12351593.
36. Urba SG, Moon J, Giri PG, Adelstein DJ, Hanna E, Yoo GH, et al. Organ preservation for advanced resectable cancer of the base of tongue and hypopharynx: a Southwest Oncology Group Trial. J Clin Oncol 2005, 23(1):88-95. 10.1200/JCO.2005.04.017, 15625363.
37. Marur S, D'Souza G, Westra WH, Forastiere AA. HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol 2010, 11:781-789. 10.1016/S1470-2045(10)70017-6, 20451455.
38. Lassen P, Eriksen JG, Hamilton-Dutoit S, Tramm T, Alsner J, Overgaard J. HPV-associated p16-expression and response to hypoxic modification of radiotherapy in head and neck cancer. Radiother Oncol 2010, 94(1):30-5. 10.1016/j.radonc.2009.10.008, 19910068.
39. Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tan PF, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010, 363(1):24-35. 10.1056/NEJMoa0912217, 20530316.
40. Grabenbauer GG, Rodel C, Ernst-Stecken A, Brunner T, Hornung J, Kittel K, et al. Neck dissection following radiochemotherapy of advanced head and neck cancer--for selected cases only?. Radiother Oncol 2003, 66(1):57-63. 10.1016/S0167-8140(02)00193-7, 12559521.
41. Clayman GL, Johnson CJ, Morrison W, Ginsberg L, Lippman SM. The role of neck dissection after chemoradiotherapy for oropharyngeal cancer with advanced nodal disease. Arch Otolaryngol Head Neck Surg 2001, 127(2):135-9.